{
    "id": 26668,
    "fullName": "TCF3 - PBX1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "TCF3-PBX1 (also reported as E2A-PBX1) results from the fusion of TCF3 and PBX1, resulting in a gain of function as demonstrated by increased phosphorylation of PLC gamma 2 via activation of target genes (PMID: 27758892). TCF3-PBX1 is associated with acute lymphocytic leukemia (PMID: 27758892, PMID: 30563523).",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                },
                {
                    "id": 18437,
                    "pubMedId": 30563523,
                    "title": "A novel PAX5 rearrangement in TCF3-PBX1 acute lymphoblastic leukemia: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30563523"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6929,
        "geneSymbol": "TCF3",
        "terms": [
            "TCF3",
            "AGM8",
            "bHLHb21",
            "E2A",
            "E47",
            "ITF1",
            "p75",
            "TCF-3",
            "VDIR"
        ]
    },
    "variant": "TCF3 - PBX1",
    "createDate": "06/29/2017",
    "updateDate": "03/25/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5087,
                "geneSymbol": "PBX1",
                "terms": [
                    "PBX1",
                    "CAKUHED"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11340,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Sprycel (dasatinib) and PRT062607 resulted in synergistic cell growth inhibition of BCR positive leukemia cells harboring TCF3-PBX1 in culture (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 5949,
                "therapyName": "Dasatinib + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11330,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCR positive leukemia calls harboring TCF3-PBX1 demonstrated cell growth inhibition when treated with Sprycel (dasatinib) in culture (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11334,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCR positive leukemia cells harboring TCF3-PBX1 demonstrated inhibition of cell proliferation when treated with RK22446 in culture (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 5946,
                "therapyName": "RK22446",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11335,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCR positive leukemia cells harboring TCF3-PBX1 demonstrated inhibition of cell growth in culture and prolonged disease survival in cell line xenograft models when treated with PRT062607 (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 3781,
                "therapyName": "PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11337,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCR positive leukemia cells harboring TCF3-PBX1 demonstrated inhibition of cell growth in culture and prolonged disease survival in cell line xenograft models when treated with A-770041 (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 5945,
                "therapyName": "A-770041",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11338,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of A-770041 and PRT062607 resulted in synergistic cell growth inhibition in BCR positive leukemia cells harboring TCF3-PBX1 in culture (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 5947,
                "therapyName": "A-770041 + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11339,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of A-770041 and R406 resulted in synergistic cell growth inhibition in BCR positive leukemia cells harboring TCF3-PBX1 in culture (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 5948,
                "therapyName": "A-770041 + Tamatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27960,
            "profileName": "TCF3 - PBX1",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27961,
            "profileName": "TCF3 - PBX1 BCR pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}